The role of the neoadjuvant chemotherapy in the treatment of the tumor of rectal cancer

OBJECTIVE: To evaluate oncological and surgical outcome of patients submitted to neoadjuvant therapy for advanced rectal cancer. PATIENTS AND METHOD: One hundred thirty eight patients (86 male, 52 female, mean age 61.4 years), with tumour of lower (58; 42%), middle (66; 48%), upper rectum (14; 10%), showing a clinical stage II (23; 17%) or III (115; 83%) and with an average distance from anal verge of 6.5 cm, submitted to fractionated "long-course" RT with CT locally staged by US and MR before and after neoadjuvant therapy and operated on after 4-6 weeks by its end. RESULTS: Surgical procedures (71 of which laparoscopic) were: 114 AR (83.8%), 19 APR (14%) and 3 TEM (2.2%). Mean nodal-sampling was 14.9. A complete or partial response was observed in 48.5% of the patients (671138). With a mean follow-up of 30 months, local recurrence rate was 5.7%. Five-years overall survival and disease-free-survival were respectively 73% and 60%. DISCUSSION: We observed a significant clinical (p < 0.004) and pathological (p < 0.005) downstaging. Pre-treatment clinical stage was not significant. On the contrary, postoperative yTNM was significant for yT (p < 0.001) and yN (p < 0.0003). Non-responder patients had worse prognosis (5-years survival 30%). The variable with higher prognostic significance was yN (p < 0.0003.), especially if we distinguish NI by N2 (p < 0.0004) . CONCLUSIONS: The response to neoadjuvant therapy represents a significant prognostic variable.